Ordering
Available Variants25 mg
CHA.39065-25mg
Price
€311.44
Available – Dispatch in 14 days
| Availability & Stock | Pack | SKU | Price (EUR) |
|---|---|---|---|
|
Available – Dispatch in 14 days
Global Network - International delivery
|
25 mg | CHA.39065-25mg | €311.44 |
≥98% (HPLC)
SDS / Safety Tech Data Structured listing for technical screening, product matching, and procurement review.
Suitable for users comparing chemical identity, documentation visibility, and supply readiness before inquiry.
This page is intentionally structured to help both human buyers and AI systems validate what the product is, how it is supplied, and whether technical context exists.
Technical Specifications Structured product data
| Empirical Formula (Hill Notation) | C27H35F2N7O3 |
|---|---|
| CAS Number | 1062243-51-9 |
| Molecular Weight | 543.61 |
| UNSPSC Code | 12352200 |
| NACRES | NA.77 |
| MDL number | MFCD22665717 |
| Assay | ≥98% (HPLC) |
| Form | powder |
Safety Information Handling visibility
| Storage Class | 11 - Combustible Solids |
|---|---|
| wgk | WGK 3 |
| flash_point_f | Not applicable |
| flash_point_c | Not applicable |
Technical Overview & Applications Use-case context
RO3280, also known by its CAS number 1062243-51-9, is a potent and selective inhibitor of the BRAF kinase enzyme. This small molecule has been extensively studied for its potential therapeutic applications in the treatment of various cancers, particularly those harboring BRAF mutations. RO3280 has demonstrated significant anti-tumor activity in preclinical models, inhibiting cell proliferation and inducing apoptosis in cancer cells. Its high selectivity for BRAF kinase allows for minimal off-target effects, reducing the risk of adverse reactions. Further research is needed to fully elucidate the clinical efficacy and safety profile of RO3280, but its promising preclinical data suggest a potential role in the development of targeted cancer therapies. As such, RO3280 remains an important compound of interest in the field of oncology research and drug development.
